Ipsen outlays $1bn for China-based Simcere’s preclinical ADC
Ipsen has added a Chinese-developed antibody drug conjugate (ADC) to its pipeline in a deal that could top $1bn, cementing …
Post
-
-
Magazine: Biopharma’s 2025 M&A boom
As we head into the new year, now is the time to look back on the activity seen in the …
-
Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for Lunsumio …
-
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
Novo Nordisk has ushered in a new era of obesity treatment – gaining the first US Food and Drug Administration …
-
Samsung Biologics to acquire Human Genome Sciences
Samsung Biologics has entered into a definitive agreement, through its subsidiary Samsung Biologics America, to acquire Human Genome Sciences from …
-
Pharma positions itself for 2026 amid an evolving US landscape
After President Donald Trump’s administration took office in early 2025, a series of policy changes have directly impacted the pharma …
-
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push
BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies …
-
UK approves Gilead’s twice-yearly HIV PrEP drug
Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering …
-
Trump administration ties pricing deals with another nine pharma companies
Nine big pharma companies have reached agreements with the Trump administration to lower prices for certain drugs in the US …
-
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, …
-
AstraZeneca pulls Andexxa from US market after post-marketing fatalities
AstraZeneca has pulled its anticoagulant therapy, Andexxa (recombinant coagulation factor Xa), from the US market after patient fatalities. This follows rising …
-
MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan
MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem cell therapy for moderate …
-
Pharmaceutical Technology Excellence Awards 2025: Tech Mahindra
Tech Mahindra has built a broad presence across the life sciences value chain, from clinical and regulatory services through manufacturing …
-
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the pharmaceutical supply …
-
Nxera seeks schizophrenia programme buyer after Boehringer snub
Japan-based Nxera Pharma is seeking buyers for its Phase II-ready schizophrenia programme after Boehringer Ingelheim decided not to exercise a …
